Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells.
- Author:
Peng GUO
1
;
Dongxian PENG
;
Xiangpeng XIONG
;
Sainan ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; pharmacology; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; metabolism; Neoplasms, Glandular and Epithelial; metabolism; pathology; Ovarian Neoplasms; metabolism; pathology; Real-Time Polymerase Chain Reaction; Transfection
- From: Journal of Southern Medical University 2015;35(11):1624-1627
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of microRNA-100(miR-100) and the relationship with cisplatin resistance in human ovarian epithelial cancer SKOV3/DDP cells.
METHODSThe SKOV3/DDP cells were transfected with the mimics or inhibitor of miR-100 or negative control RNA (NC) or inhibitor negative control RNA (inhibitor NC) by lipofectamine 2000. The experiment was divided into six groups: SKOV3 group, SKOV3/DDP group, miR-100 mimices group, NC group, miR-100 inhibitor group and inhibitor NC group. The expression of miR-100 and the cisplatin IC50 were measured by real-time PCR and CCK8 assay respectively.
RESULTS(1)The cisplatin resistance index of SKOV3/DDP was 2.23; (2)The express level of miR-100 in SKOV3/DDP cells was significantly lower than that in SKOV3 cells (P<0.001); (3)After transfected with miR-100 mimics, SKOV3/DDP cells showed that the level of miR-100 was 38.29 times higher than that in the NC group(P<0.01). The cisplatin IC50 of miR-100 mimices group was significantly lower than that in the NC group (P<0.001); (4) After transfected with miR-100 inhibitor, the level of miR-100 0f SKOV3/DDP was decreased by 97.7%. The cisplatin IC50 of miR-100 inhibitor group was significantly increased as compared with that in the inhibitor NC group (P<0.001).
CONCLUSIONThe expression of miR-100 is downregulated in SKOV3/DDP cells. Overexpressing miR-100 may effectively increase the sensitivity to cisplatin of human ovarian epithelial cancer SKOV3/DDP cells and may reverse cisplatin-resistance of EOC (epithelial ovarian cancer).
